PuSH - Publication Server of Helmholtz Zentrum München: Inhibition of homologous recombination and promotion of mutagenic repair of DNA double-strand breaks underpins arabinoside-nucleoside analogue radiosensitization.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Magin, S.* ; Papaioannou, M.* ; Saha, J.* ; Staudt, C. ; Iliakis, G.*

Inhibition of homologous recombination and promotion of mutagenic repair of DNA double-strand breaks underpins arabinoside-nucleoside analogue radiosensitization.

Mol. Cancer Ther. 14, 1424-1433 (2015)

DOI

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

In concurrent chemoradiotherapy, drugs are used to sensitize tumors to ionizing radiation. Although a spectrum of indications for simultaneous treatment with drugs and radiation has been defined, the molecular mechanisms underpinning tumor radiosensitization remain incompletely characterized for several such combinations. Here, we investigate the mechanisms of radiosensitization by the arabinoside nucleoside analogue 9-b-D-arabinofuranosyladenine (araA) placing particular emphasis on the repair of DNA double-strand breaks (DSB), and compare the results to those obtained with fludarabine (F-araA) and cytarabine (araC). Postirradiation treatment with araA strongly sensitizes cells to ionizing radiation, but leaves unchanged DSB repair by NHEJ in logarithmically growing cells, in sorted G1 or G2 phase populations, as well as in cells in the plateau phase of growth. Notably, araA strongly inhibits DSB repair by homologous recombination (HRR), as assessed by scoring ionizing radiation-induced RAD51 foci, and in functional assays using integrated reporter constructs. Cells compromised in HRR by RNAi-mediated transient knockdown of RAD51 show markedly reduced radiosensitization after treatment with araA. Remarkably, mutagenic DSB repair compensates for HRR inhibition in araA-treated cells. Compared with araA, F-araA and araC are only modestly radiosensitizing under the conditions examined. We propose that the radiosensitizing potential of nucleoside analogues is linked to their ability to inhibit HRR and concomitantly promote the errorprone processing of DSBs. Our observations pave the way to treatment strategies harnessing the selective inhibitory potential of nucleoside analogues and the development of novel compounds specifically utilizing HRR inhibition as a means of tumor cell radiosensitization.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

ISSN (print) / ISBN 1535-7163

e-ISSN 1538-8514

Journal Molecular Cancer Therapeutics

Quellenangaben Volume: 14, Issue: 6, Pages: 1424-1433

Publisher American Association for Cancer Research (AACR)

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Radiation Protection (ISS)